The C-terminal c-Src kinase (Csk) is a 50-kDa cytosolic tyrosine kinase expressed in all examined cell types. Structurally, it resembles the Src family kinases in having SH3, SH2 and kinase domains, but it differs from Src kinases in lacking an N-terminal extension with a myristylation sequence motif, a tyrosine autophosphorylation site, and a C-terminal regulatory tyrosine phosphorylation site.

The physiological function of Csk is to phosphorylate the negative regulatory tyrosine residue in the C-terminus of all Src family kinases. In fact, Csk is probably the only kinase that efficiently phosphorylates this site in vivo, making Csk the general negative regulator of all Src family kinase-mediated events in cells. It is unclear if CSK has any other substrates.

Csk is encoded by an essential gene, the deletion of which is early embryonic lethal in mice due to defects in closure of the neural tube. Transformed embryonic fibroblasts from these animals display a near complete loss of phosphorylation of the C-terminal negative regulatory site in Src family kinases, significantly elevated catalytic activity of all Src like kinases, and constitutive hyperphosphorylation of their substrates.

In contrast to other tyrosine kinases, Csk is apparently not regulated by tyrosine phosphorylation. In fact, the activation loop is shorter than in other kinases and it does not contain any tyrosine residues. Instead, Csk is regulated by phosphorylation of a serine residues, S364, within the larger lobe of its catalytic domain. This site is phosphorylated by cAMP-dependent kinase and results in a several fold activation of Csk. In T cells, agents that elevate cAMP levels (e.g. prostaglandin E2 or membrane-permeable cAMP analogs) caused the phosphorylation of Csk at S364, activated Csk, suppressed Src family kinases, and prevented T cell activation. A phosphorylation site mutant of Csk prevented these responses, suggesting that Csk may be a critical target for cAMP-induced immune suppression.

An important regulator of Csk function is a transmembrane molecule, termed PAG or Cbp, which specifically binds the Csk SH2 domain when phosphorylated. PAG/Cbp is anchored to lipid rafts and is phosphorylated on tyrosine in resting cells, thus anchoring Csk in the subcellular compartment that is enriched in Src family kinases. Upon T cell antigen-receptor triggering, PAG/Cbp is transiently dephosphorylated leading to the dissociation of Csk. This allows lipid raft-located Src family kinases (Lck and Fyn in T cells) to remain active and phosphorylate receptor subunits and other molecules. After a few minutes, PAG/Cbp is again phosphorylated and Csk returns to the lipid rafts. This coincides with the downturn of tyrosine phosphorylation of Src family kinase substrates.

Csk also associates through its SH3 domain with the protein tyrosine phosphatases PTP-PEST and LYP (mouse ortholog is called PEP). As these phosphatases dephosphorylate the positive regulatory tyrosine residue in Src family kinases, it is thought that they synergize with Csk by jointly targeting and suppressing these kinases. Csk has also been shown to bind paxillin and other adapter proteins.

The Csk-homologous kinase (Chk) is 53% identical to Csk and shares the same overall structure of SH3-SH2-kinase domains, but has somewhat longer N- and C-terminal extensions. There are two splice variants of Chk, 52 and 57 kDa, expressed predominantly in brain and hematopoietic cells. Chk expression can be upregulated by several growth factors and mitogen in leukocytes. Chk can phosphorylate Src family kinases in vitro and in breast cancer cells upon recruitment and binding to the ErbB-2/neu receptor kinase.

The Table below contains accepted modulators and additional information. For a list of additional products, see the "Materials" section below.

Materials
Loading

References

1.
Bergman M, Mustelin T, Oetken C, Partanen J, Flint N, Amrein K, Autero M, Burn P, Alitalo K. 1992. The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity.. The EMBO Journal. 11(8):2919-2924. http://dx.doi.org/10.1002/j.1460-2075.1992.tb05361.x
2.
Brdic?ka T, Pavlis?tová D, Leo A, Bruyns E, Kor?ínek V, Angelisová P, Scherer J, Shevchenko A, Shevchenko A, Hilgert I, et al. 2000. Phosphoprotein Associated with Glycosphingolipid-Enriched Microdomains (Pag), a Novel Ubiquitously Expressed Transmembrane Adaptor Protein, Binds the Protein Tyrosine Kinase Csk and Is Involved in Regulation of T Cell Activation. 191(9):1591-1604. http://dx.doi.org/10.1084/jem.191.9.1591
3.
Chow LML, Fournel M, Davidson D, Veillette A. 1993. Negative regulation of T-cell receptor signalling by tyrosine protein kinase p50csk. Nature. 365(6442):156-160. http://dx.doi.org/10.1038/365156a0
4.
Davidson D, Cloutier J, Gregorieff A, Veillette A. 1997. Inhibitory Tyrosine Protein Kinase p50cskIs Associated with Protein-tyrosine Phosphatase PTP-PEST in Hemopoietic and Non-hemopoietic Cells. J. Biol. Chem.. 272(37):23455-23462. http://dx.doi.org/10.1074/jbc.272.37.23455
5.
Ia KK, Mills RD, Hossain MI, Chan K, Jarasrassamee B, Jorissen RN, Cheng H. 2010. Structural elements and allosteric mechanisms governing regulation and catalysis of CSK-family kinases and their inhibition of Src-family kinases. Growth Factors. 28(5):329-350. http://dx.doi.org/10.3109/08977194.2010.484424
6.
Imamoto A, Soriano P. 1993. Disruption of the csk gene, encoding a negative regulator of Src family tyrosine kinases, leads to neural tube defects and embryonic lethality in mice. Cell. 73(6):1117-1124. http://dx.doi.org/10.1016/0092-8674(93)90641-3
7.
Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, Nagai K, Tarakhovsky A, Okada M. 2000. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature. 404(6781):999-1003. http://dx.doi.org/10.1038/35010121
8.
Kim S, Zagozdzon R, Meisler A, Baleja JD, Fu Y, Avraham S, Avraham H. 2002. Csk Homologous Kinase (CHK) and ErbB-2 Interactions Are Directly Coupled with CHK Negative Growth Regulatory Function in Breast Cancer. J. Biol. Chem.. 277(39):36465-36470. http://dx.doi.org/10.1074/jbc.m206018200
9.
Nada S, Okada M, MacAuley A, Cooper JA, Nakagawa H. 1991. Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src. Nature. 351(6321):69-72. http://dx.doi.org/10.1038/351069a0
10.
Nada S, Yagi T, Takeda H, Tokunaga T, Nakagawa H, Ikawa Y, Okada M, Aizawa S. 1993. Constitutive activation of Src family kinases in mouse embryos that lack Csk. Cell. 73(6):1125-1135. http://dx.doi.org/10.1016/0092-8674(93)90642-4
11.
1991. CSK: a protein-tyrosine kinase involved in regulation of Src family kinases. J. Biol. Chem..(266):24249-24252.
12.
Okada M. 2012. Regulation of the Src Family Kinases by Csk. Int. J. Biol. Sci.. 8(10):1385-1397. http://dx.doi.org/10.7150/ijbs.5141
13.
Tasken K. 2006. Negative regulation of T-cell receptor activation by the cAMP-PKA-Csk signalling pathway in T-cell lipid rafts. Front Biosci. 11(1):2929. http://dx.doi.org/10.2741/2022
14.
Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Hor?ej??? V, Schraven B, Rolstad B, Mustelin T, Taskén K. 2001. Release from Tonic Inhibition of T Cell Activation through Transient Displacement of C-terminal Src Kinase (Csk) from Lipid Rafts. J. Biol. Chem.. 276(31):29313-29318. http://dx.doi.org/10.1074/jbc.c100014200
15.
Vang T, Torgersen KM, Sundvold V, Saxena M, Levy FO, Skålhegg BS, Hansson V, Mustelin T, Taskén K. 2001. Activation of the Cooh-Terminal Src Kinase (Csk) by Camp-Dependent Protein Kinase Inhibits Signaling through the T Cell Receptor. 193(4):497-508. http://dx.doi.org/10.1084/jem.193.4.497
16.
Xi B, Shen Y, Reilly KH, Wang X, Mi J. 2013. Recapitulation of four hypertension susceptibility genes (CSK, CYP17A1, MTHFR, and FGF5) in East Asians. Metabolism. 62(2):196-203. http://dx.doi.org/10.1016/j.metabol.2012.07.008

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.